Micardis and Similar Blood Pressure Drugs May Increase Risk of Cancer
Angiotensin-receptor blockers, commonly known as A.R.B.’s, may increase the risk of cancer, the New York Times reports. The popular drugs used by tens of millions of patients to treat hypertension, heart failure and diabetes-related kidney damage might increase the risk of cancer by a total of 11 percent and the risk of lung cancer by 25 percent.
A recent analysis of five studies showed one additional case of cancer for every 105 patients who take the drugs for at least four years. Most of that analysis was drawn from telmisartan, which is marketed as Micardis.
Because of their effects on blood pressure, the authors of the analysis urged those using the drugs to continue taking them, at least until they have a chance to consult with their doctors about other medicines. Other blood pressure drugs likely can be substituted for the A.R.B.’s but, like the authors suggested, patients should consult their doctors first.
Legal analysis by Shawn Cantley [profile], Shawn's Mail:
Drug manufacturers owe many duties to the users of their products. Specifically, they have a duty to not design or manufacture unreasonably dangerous drugs. Furthermore, they have a duty to warn users of the dangers of their medicines so individuals can make informed decisions. If they breach those duties and that breach injures someone the drug company may face civil liability.
As more facts develop, the makers of Micardis and other A.R.B.'s could face civil liability if they violated those duties and caused injuries. If you or someone you know has been injured by a dangerous drug you should consider speaking to an attorney with experience in these matters. They can provide valuable counsel as well as preserve evidence and protect your rights.
For the New York Times article click here.
